# Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

> **NCT01660295** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** Certoparin 3,000 IU Once Daily
- **DRUG:** Certoparin 3,000 IU Twice a Day
- **DRUG:** Certoparin 8,000 IU Once Daily
- **DRUG:** Certoparin 8,000 IU Twice a Day

## Key facts

- **NCT ID:** NCT01660295
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-06
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660295, "Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01660295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*